Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Oxaliplatin 49Fluorouracil 45Leucovorin 42Capecitabine 40Irinotecan 31Bevacizumab 31Radiotherapy 24Cetuximab 23Radiation 13Panitumumab 13Folfox protocol 10Surgical Procedures, Operative 9IFL protocol 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6aflibercept 5Immunohistochemistry 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Fluorodeoxyglucose F18 4Floxuridine 4Celecoxib 4trifluridine tipiracil drug combination 3dehydroftorafur 3XELOX 3Sorafenib 3Ramucirumab 3Neoadjuvant Therapy 3Erlotinib Hydrochloride 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rectal Neoplasms × Rifaximin × Clear all
NCT01345175 2024-05-14

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
69 enrolled 9 charts
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡